ABLE, DUKE and OSHL conduct workshop on Meeting the Challenges of Developing New Anticancer Therapies.
The oncology community and the pharmaceutical industry have been shifting the focus of clinical research towards performing trials in emerging markets like India due to the positivessuch as faster recruitment timelines, patient populations who could benefit from trials with cutting edge therapeutics and also lower overall costs. As cancer therapies are often targeted on specific genomic mutations, the specific profiles of patients in India would also determine the optimal use of these therapies locally. Another significant trend has been that innovative research and development oftentakes place in smallerbiotechnology firms, and not exclusively in the larger multi-national pharmaceutical companies. Therefore, the oncology communitieswould benefit in supporting the efficient testing of innovative products locallyand thereby have early access to these innovations.
The Association of Biotechnology Led Enterprises (ABLE), the DUKE University and The Open Source Health Laboratories (OSHL) organized a workshop on Meeting the Challenges of Developing New Anticancer Therapies in New Delhi on September 17th that attracted interest and participation from public agencies and private companies.
The workshop was led by internationally renowned cancer researcher, Dr. H. Kim Lyerly of Duke University who discussed methods of developing new anticancer therapies in India and the U.S. for worldwide distribution. Strategic planning, clinical trial initiatives, translational research, and regulatory elements of the drug development process were discussed. Attendees were provided with a broad overview of the annual USFDA workshop whose goal is to expedite the development and validation for new anticancer and cancer prevention agents.
Dr. Lyerly commented that, "Indian pharma and biotech companies and public institutions have researchers and facilities that are capable of researching and developing new anti-cancer drugs. The traditional Indian medicine systems too have several remedies but in order for them to be validated for global use they too need to go through the same procedure as any other chemical or biotech drug. The workshop
will surely help in improving the drug development processes of anti-cancer drugs in India."
Dr Vijay Chandru, CEO of Strand Life Sciences and EC member (ABLE) observed 'We are grateful to Dr. Lyerly for having come all the way to offer his expert advice on these topics. Drug Development is one of the most expensive aspects of getting drugs to the market. The prowess of researchers and regulators in Indiain this highly regulated space depends on timely knowledge of global standards and benchmarks and how to approach them. The BioPharma sector in India is active in oncology therapeutics with global market aspirations and welcomes such interactions withthought leaders in development."
Charles Maynard, ED of OSHL commented "this workshop is one example of the types of international collaborations that OHSL seeks to initiate, nurture and develop. The speed with which global collaborative medical research is being launched continues to be enigmatic and therefore it is necessary for organizations such as OHSL to exist. From our vantage point, we can leverage a great deal of resources to facilitate the successful stewardship of these medical research projects. We have done it and therefore we understand what it takes! We look forward to a mutually beneficial and rewarding relationship with the various medical research communities and organizations in Asia such as ABLE as we do in other parts of the world."
For any query with respect to this article or any other content requirement, please contact Editor at email@example.com
Copyright HT Media Ltd.
Provided by Syndigate.info an Albawaba.com company
|Printer friendly Cite/link Email Feedback|
|Date:||Sep 18, 2012|
|Previous Article:||O2 Launches new range of Chesterfield sofas.|
|Next Article:||Starting September 22, Radio Channels across India will feature programmes on the GRE(R) revised General Test.|